PUBLISHER: 360iResearch | PRODUCT CODE: 1602691
PUBLISHER: 360iResearch | PRODUCT CODE: 1602691
Alvimopan Market by Therapeutic Application (Opioid-Induced Constipation, Postoperative Ileus Prevention), End-User (Hospitals, Surgical Centers) - Global Forecast 2025-2030
The Alvimopan Market was valued at USD 6.20 billion in 2023, expected to reach USD 6.51 billion in 2024, and is projected to grow at a CAGR of 5.23%, to USD 8.87 billion by 2030.
Alvimopan is a peripherally acting μ-opioid receptor antagonist primarily used to accelerate gastrointestinal recovery following bowel resection surgeries by mitigating opioid-induced gastrointestinal side effects. The necessity of Alvimopan stems from its critical role in enhancing postoperative recovery rates, reducing hospital stays, and decreasing healthcare costs, particularly in light of the increasing number of surgical procedures worldwide. It is predominantly applied in the healthcare setting by hospitals and surgical centers as a postoperative treatment agent. Alvimopan's end-use scope extends to the pharmaceutical sector with a focus on postoperative care and enhanced patient management protocols. The increasing emphasis on minimally invasive surgeries and rapid recovery protocols within healthcare systems is a significant growth factor for this market. Potential opportunities lie in expanding indications for its use beyond gastrointestinal recovery and exploring combination drug therapies that could widen its applicability. Engaging in strategic partnerships with healthcare institutions can enhance market penetration and reach. However, limitations such as regulatory challenges, high cost, and strict administration protocols pose significant hurdles. Resistance due to potential cardiovascular risks and associated stringent guidelines may also deter market expansion. Innovation opportunities exist in enhancing the bioavailability and efficacy of Alvimopan through advanced drug delivery systems, such as nanoparticle-based technologies or harnessing AI-driven drug design strategies to optimize its therapeutic efficacy. Research could focus on developing a broader spectrum μ-opioid receptor antagonist that retains the benefits of Alvimopan while reducing risks. The market for Alvimopan is niche and highly specialized, driven by strong clinical evidence supporting its effectiveness, but it requires navigating complex regulatory landscapes and demonstrating safety to sustain growth. Understanding market dynamics and integrating tailored marketing strategies can provide competitive advantages in this evolving domain.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2023] | USD 6.20 billion |
| Estimated Year [2024] | USD 6.51 billion |
| Forecast Year [2030] | USD 8.87 billion |
| CAGR (%) | 5.23% |
Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Alvimopan Market
The Alvimopan Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.
- Market Drivers
- Rise in surgical interventions including abdominal surgeries
- Growing awareness and management strategies for opioid-induced complications
- Improved healthcare facilities worldwide
- Market Restraints
- Strict regulations and long approval processes
- Market Opportunities
- R&D initiatives for exploring therapeutic applications of alvimopan
- Increasing investments in public and private healthcare infrastructure
- Market Challenges
- Risk of associated side effects of alvimopan
Porter's Five Forces: A Strategic Tool for Navigating the Alvimopan Market
Porter's five forces framework is a critical tool for understanding the competitive landscape of the Alvimopan Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.
PESTLE Analysis: Navigating External Influences in the Alvimopan Market
External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Alvimopan Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.
Market Share Analysis: Understanding the Competitive Landscape in the Alvimopan Market
A detailed market share analysis in the Alvimopan Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.
FPNV Positioning Matrix: Evaluating Vendors' Performance in the Alvimopan Market
The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Alvimopan Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.
Strategy Analysis & Recommendation: Charting a Path to Success in the Alvimopan Market
A strategic analysis of the Alvimopan Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.
Key Company Profiles
The report delves into recent significant developments in the Alvimopan Market, highlighting leading vendors and their innovative profiles. These include Adolor Corporation, Adooq Bioscience LLC, Hikma Pharmaceuticals PLC, Manus Aktteva Biopharma LLP, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd..
Market Segmentation & Coverage
This research report categorizes the Alvimopan Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Based on Therapeutic Application, market is studied across Opioid-Induced Constipation and Postoperative Ileus Prevention.
- Based on End-User, market is studied across Hospitals and Surgical Centers.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
The report offers a comprehensive analysis of the market, covering key focus areas:
1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.
2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.
3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.
4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.
5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.
The report also answers critical questions to aid stakeholders in making informed decisions:
1. What is the current market size, and what is the forecasted growth?
2. Which products, segments, and regions offer the best investment opportunities?
3. What are the key technology trends and regulatory influences shaping the market?
4. How do leading vendors rank in terms of market share and competitive positioning?
5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rise in surgical interventions including abdominal surgeries
- 5.1.1.2. Growing awareness and management strategies for opioid-induced complications
- 5.1.1.3. Improved healthcare facilities worldwide
- 5.1.2. Restraints
- 5.1.2.1. Strict regulations and long approval processes
- 5.1.3. Opportunities
- 5.1.3.1. R&D initiatives for exploring therapeutic applications of alvimopan
- 5.1.3.2. Increasing investments in public and private healthcare infrastructure
- 5.1.4. Challenges
- 5.1.4.1. Risk of associated side effects of alvimopan
- 5.1.1. Drivers
- 5.2. Market Segmentation Analysis
- 5.2.1. Therapeutic Application: Diverse scope of applications for easing opioid-Induced constipation
- 5.2.2. End-User: Increasing preference for alvimopan in surgical centers for treating postoperative ileus
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
- 5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental
6. Alvimopan Market, by Therapeutic Application
- 6.1. Introduction
- 6.2. Opioid-Induced Constipation
- 6.3. Postoperative Ileus Prevention
7. Alvimopan Market, by End-User
- 7.1. Introduction
- 7.2. Hospitals
- 7.3. Surgical Centers
8. Americas Alvimopan Market
- 8.1. Introduction
- 8.2. Argentina
- 8.3. Brazil
- 8.4. Canada
- 8.5. Mexico
- 8.6. United States
9. Asia-Pacific Alvimopan Market
- 9.1. Introduction
- 9.2. Australia
- 9.3. China
- 9.4. India
- 9.5. Indonesia
- 9.6. Japan
- 9.7. Malaysia
- 9.8. Philippines
- 9.9. Singapore
- 9.10. South Korea
- 9.11. Taiwan
- 9.12. Thailand
- 9.13. Vietnam
10. Europe, Middle East & Africa Alvimopan Market
- 10.1. Introduction
- 10.2. Denmark
- 10.3. Egypt
- 10.4. Finland
- 10.5. France
- 10.6. Germany
- 10.7. Israel
- 10.8. Italy
- 10.9. Netherlands
- 10.10. Nigeria
- 10.11. Norway
- 10.12. Poland
- 10.13. Qatar
- 10.14. Russia
- 10.15. Saudi Arabia
- 10.16. South Africa
- 10.17. Spain
- 10.18. Sweden
- 10.19. Switzerland
- 10.20. Turkey
- 10.21. United Arab Emirates
- 10.22. United Kingdom
11. Competitive Landscape
- 11.1. Market Share Analysis, 2023
- 11.2. FPNV Positioning Matrix, 2023
- 11.3. Competitive Scenario Analysis
- 11.3.1. Hikma Pharmaceuticals Launches Alvimopan Capsules for Enhanced Gastrointestinal Recovery in the US
- 11.4. Strategy Analysis & Recommendation
Companies Mentioned
- 1. Adolor Corporation
- 2. Adooq Bioscience LLC
- 3. Hikma Pharmaceuticals PLC
- 4. Manus Aktteva Biopharma LLP
- 5. Merck & Co., Inc.
- 6. Teva Pharmaceutical Industries Ltd.
LIST OF FIGURES
- FIGURE 1. ALVIMOPAN MARKET RESEARCH PROCESS
- FIGURE 2. ALVIMOPAN MARKET SIZE, 2023 VS 2030
- FIGURE 3. GLOBAL ALVIMOPAN MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. GLOBAL ALVIMOPAN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 5. GLOBAL ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. GLOBAL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2030 (%)
- FIGURE 7. GLOBAL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 8. GLOBAL ALVIMOPAN MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 9. GLOBAL ALVIMOPAN MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 10. AMERICAS ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 11. AMERICAS ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 12. UNITED STATES ALVIMOPAN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 13. UNITED STATES ALVIMOPAN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 14. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 15. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 18. ALVIMOPAN MARKET SHARE, BY KEY PLAYER, 2023
- FIGURE 19. ALVIMOPAN MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
- TABLE 1. ALVIMOPAN MARKET SEGMENTATION & COVERAGE
- TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
- TABLE 3. GLOBAL ALVIMOPAN MARKET SIZE, 2018-2030 (USD MILLION)
- TABLE 4. GLOBAL ALVIMOPAN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 5. GLOBAL ALVIMOPAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 6. ALVIMOPAN MARKET DYNAMICS
- TABLE 7. GLOBAL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 8. GLOBAL ALVIMOPAN MARKET SIZE, BY OPIOID-INDUCED CONSTIPATION, BY REGION, 2018-2030 (USD MILLION)
- TABLE 9. GLOBAL ALVIMOPAN MARKET SIZE, BY POSTOPERATIVE ILEUS PREVENTION, BY REGION, 2018-2030 (USD MILLION)
- TABLE 10. GLOBAL ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 11. GLOBAL ALVIMOPAN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 12. GLOBAL ALVIMOPAN MARKET SIZE, BY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 13. AMERICAS ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 14. AMERICAS ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 15. AMERICAS ALVIMOPAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 16. ARGENTINA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 17. ARGENTINA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 18. BRAZIL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 19. BRAZIL ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 20. CANADA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 21. CANADA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 22. MEXICO ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 23. MEXICO ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 24. UNITED STATES ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 25. UNITED STATES ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 26. UNITED STATES ALVIMOPAN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
- TABLE 27. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 28. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 29. ASIA-PACIFIC ALVIMOPAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 30. AUSTRALIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 31. AUSTRALIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 32. CHINA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 33. CHINA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 34. INDIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 35. INDIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 36. INDONESIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 37. INDONESIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 38. JAPAN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 39. JAPAN ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 40. MALAYSIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 41. MALAYSIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 42. PHILIPPINES ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 43. PHILIPPINES ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 44. SINGAPORE ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 45. SINGAPORE ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 46. SOUTH KOREA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 47. SOUTH KOREA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 48. TAIWAN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 49. TAIWAN ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 50. THAILAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 51. THAILAND ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 52. VIETNAM ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 53. VIETNAM ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 54. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 55. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 56. EUROPE, MIDDLE EAST & AFRICA ALVIMOPAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 57. DENMARK ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 58. DENMARK ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 59. EGYPT ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 60. EGYPT ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 61. FINLAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 62. FINLAND ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 63. FRANCE ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 64. FRANCE ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 65. GERMANY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 66. GERMANY ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 67. ISRAEL ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 68. ISRAEL ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 69. ITALY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 70. ITALY ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 71. NETHERLANDS ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 72. NETHERLANDS ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 73. NIGERIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 74. NIGERIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 75. NORWAY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 76. NORWAY ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 77. POLAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 78. POLAND ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 79. QATAR ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 80. QATAR ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 81. RUSSIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 82. RUSSIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 83. SAUDI ARABIA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 84. SAUDI ARABIA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 85. SOUTH AFRICA ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 86. SOUTH AFRICA ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 87. SPAIN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 88. SPAIN ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 89. SWEDEN ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 90. SWEDEN ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 91. SWITZERLAND ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 92. SWITZERLAND ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 93. TURKEY ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 94. TURKEY ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 95. UNITED ARAB EMIRATES ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 96. UNITED ARAB EMIRATES ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 97. UNITED KINGDOM ALVIMOPAN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
- TABLE 98. UNITED KINGDOM ALVIMOPAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 99. ALVIMOPAN MARKET SHARE, BY KEY PLAYER, 2023
- TABLE 100. ALVIMOPAN MARKET, FPNV POSITIONING MATRIX, 2023
